News for Galectin Therapeutics Inc. (GALT)

Additional analysis of data from the NAVIGATE trial showed statistically significant 68.1% (p=0.02) reduction in the incidence of new varices with belapectin vs

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. ( GALT), the leading developer of therapeutics that target galectin proteins, tod

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping more than 600 points on Friday. The Dow traded up 1.55% to 43,000.53 whil...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday. The Dow traded up 1.82% to 43,111.11 while ...

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 100 points on Friday. Following the market opening Friday, the Dow trade...

The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...

The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...

The Dow Jones index closed lower by over 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the compan...

Advanced melanoma is when melanoma cells spread from where they started (the primary melanoma) to other parts of the body. The advanced melanoma...

Loading... Loading... The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or c...